F
Fulcrum Therapeutics
Unlocking the mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from genetically defined diseases, particularly those with high unmet medical needs. The company focuses on rare diseases and employs a proprietary product engine to systematically identify and validate cellular drug targets. This technology aims to modulate gene expression to address the root causes of these diseases. Fulcrum Therapeutics collaborates with other industry leaders, such as MyoKardia, to discover novel targeted therapies for genetic cardiomyopathies. The company operates in the biopharmaceutical market, serving patients, healthcare providers, and research institutions. Its business model revolves around developing and commercializing innovative therapies, generating revenue through product sales, partnerships, and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Third Rock Ventures
GV
Foresite Capital
Casdin Capital
Section 32
Sanofi
6 Dimensions Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fulcrum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fulcrum Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.